ArticleCancer chemotherapy and pharmacology2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Amita Patnaik et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.